Evidence map›Paper›PMID 37277334›Full record

ArticleNPJ vaccines2023

Author Correction: Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.

Julia Ludwig, Stephen W Scally, Giulia Costa, Sandro Hoffmann, Rajagopal Murugan, Jana Lossin, Katherine Prieto, Anna Obraztsova, Nina Lobeto, Blandine Franke-Fayard and 8 more

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 4 countries.

Julia Ludwig *B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0009-0005-2624-8180
Stephen W Scally *Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-4264-7772
Giulia Costa *Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany.
Sandro HoffmannB Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-9776-1735
Rajagopal MuruganB Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-0336-7268
Jana LossinB Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Katherine PrietoProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-5773-5935
Anna ObraztsovaB Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0009-0000-8768-3921
Nina LobetoB Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Blandine Franke-FayardMalaria Research Group, Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.
Chris J JanseMalaria Research Group, Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-6410-6205
Celia LebasVaccine Formulation Institute, Plan-les-Ouates, Switzerland.
Nicolas CollinVaccine Formulation Institute, Plan-les-Ouates, Switzerland.
Spela BinterKymab a Sanofi Company, Babraham Research Campus, Cambridge, UK.
Paul KellamKymab a Sanofi Company, Babraham Research Campus, Cambridge, UK.
Elena A LevashinaVector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany. levashina@mpiib-berlin.mpg.de.
Hedda WardemannB Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. h.wardemann@dkfz.de.ORCID http://orcid.org/0000-0003-3921-5933
Jean-Philippe JulienProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada. jean-philippe.julien@sickkids.ca.ORCID http://orcid.org/0000-0001-7602-3995
German Cancer Research Center · DEUniversity of Toronto · CAKymab (United Kingdom) · GBLeiden University Medical Center · NLMax Planck Institute for Infection Biology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37277334
PMCPMC10241874
OpenAlexW4379468626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.